Mode
Text Size
Log in / Sign up

Layered risk-based biosafety measures and validated specimen pathways improve safety for healthcare workers and patientsLayered Safety Measures Protect Healthcare Workers from COVID-19 Risks

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Implement layered, activity-specific biosafety measures and validated specimen pathways to ensure healthcare worker safety.

This policy and practice review synthesizes current biosafety and infection prevention and control (IPC) measures to protect healthcare workers and patients within clinical and laboratory settings. The review emphasizes that safe practice requires a layered, risk-based approach tailored to specific clinical activities and the context of exposure. Key components include respiratory exposure control, personal protective equipment (PPE) use, and validated specimen collection and transport procedures.

Regarding specific technologies, the review notes that ultraviolet germicidal irradiation (UVGI) was investigated as a contingency for PPE shortages. However, the authors specify that UVGI's impact on microbial inactivation, filtration performance, and seal integrity requires separate validation. Similarly, while emerging technologies like CRISPR and nanomaterials may improve diagnostic turnaround times, their contribution to patient safety depends on clinical validation, quality assurance, and regulatory oversight.

The review highlights the necessity of an activity-specific approach to ensure occupational protection and health-system resilience. Clinical application of these measures should be guided by validated protocols to ensure both diagnostic reliability and the safety of healthcare personnel.

This review looked at how healthcare systems and laboratories can keep staff and patients safe during COVID-19. It focused on infection prevention, the use of personal protective equipment, and the safety of moving medical samples between locations. The review emphasizes that safety depends on using a layered approach tailored to specific tasks and risks.

One specific area looked at using ultraviolet germicidal irradiation to clean respirators during shortages. While this was studied as a backup plan, the review notes that its impact on the fit of the mask and its ability to filter air still needs more specific testing. Additionally, the review looked at new technologies like CRISPR and nanomaterials. These could make testing faster, but they require more clinical testing and oversight before they can be used reliably in hospitals.

For healthcare workers, the main takeaway is that safety comes from consistent, validated procedures. This includes everything from how samples are stored to how staff are protected during high-risk procedures. Because these findings are based on a narrative synthesis of existing practices, they serve as a guide for safety protocols rather than a new clinical treatment.

What this means for you:
Safety for healthcare workers depends on layered, risk-based measures tailored to specific clinical tasks.

Common questions

What makes a safety plan effective for healthcare workers?

Safety depends on a layered, risk-based approach. This means protection measures should be adapted to the specific clinical or laboratory activity being performed. By tailoring the safety steps to the specific task, healthcare systems can better protect workers and ensure the safety of medical services.

Is ultraviolet light safe for cleaning respirators?

Ultraviolet germicidal irradiation was studied as a backup strategy during equipment shortages. However, the review notes that its effect on the mask's fit, its filtration performance, and its ability to kill microbes still requires separate validation before it can be fully confirmed as a standard.

Can new technologies like CRISPR improve COVID-19 testing?

Emerging technologies like CRISPR and nanomaterials may improve how quickly tests are done or how accessible they are. However, their safety for patients depends on further clinical validation, quality assurance, and proper regulatory oversight before they can be integrated into standard care.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) placed substantial pressure on global healthcare systems, biosafety management, and the delivery of safe clinical services. As a critical component of infection prevention and control (IPC), biosafety contributes not only to limiting pathogen exposure but also to protecting healthcare workers, maintaining reliable diagnostic pathways, and supporting patient safety and health-service continuity. This Policy and Practice Review presents a structured narrative synthesis of a sample of literature published primarily between January 2020 and August 2026, supplemented by selected earlier foundational studies and relevant public-health guidance. The review focuses on respiratory exposure control, appropriate use and oversight of personal protective equipment (PPE), airway-management safety, emergency respirator decontamination and reuse strategies including ultraviolet germicidal irradiation (UVGI), specimen collection and transport, laboratory biosafety, and emerging diagnostic technologies. The evidence indicates that safe practice requires layered, risk-based measures adapted to the exposure context and specific clinical or laboratory activity. During severe PPE shortages, UVGI was investigated as a contingency strategy for respirator decontamination, but microbial inactivation, preservation of filtration performance, and maintenance of fit or seal integrity represent distinct outcomes and require separate validation. Safe specimen pathways similarly depend on validated collection, transport, storage, and laboratory procedures that preserve both worker safety and diagnostic reliability. Emerging CRISPR- and nanomaterial-enabled technologies may improve diagnostic accessibility or turnaround time, but their contribution to patient safety depends on clinical validation, quality assurance, regulatory oversight, and successful integration into healthcare workflows. Overall, lessons from the COVID-19 pandemic support a multilayered, activity-specific approach to biosafety that integrates occupational protection, diagnostic safety, patient safety, and health-system resilience.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.